Botensilimab/Balstilimab Clinical Activity in Refractory Sarcomas to be Presented in Oral Session at ESMO 2024
Agenus Inc. (Nasdaq: AGEN) announced that updated data from the clinical trial of botensilimab and balstilimab in refractory sarcomas will be presented at the ESMO Congress 2024 in Barcelona. The presentation will showcase updated efficacy and safety data from the ongoing Phase 1 trial, highlighting the potential of this combination therapy in treating patients with refractory sarcomas, including visceral angiosarcoma and leiomyosarcoma.
Botensilimab, a novel Fc-enhanced CTLA-4 inhibitor, and balstilimab, a PD-1 antibody, have shown promising clinical responses in multiple tumor types, including 'cold' tumors typically unresponsive to standard therapies. The presentation, titled 'Updated efficacy and safety of botensilimab plus balstilimab in patients with refractory metastatic sarcoma from an expanded phase 1 study,' will be given by Dr. Breelyn A. Wilky on September 13th, 2024.
Agenus Inc. (Nasdaq: AGEN) ha annunciato che dati aggiornati dallo studio clinico su botensilimab e balstilimab nei sarcomi refrattari saranno presentati al Congresso ESMO 2024 a Barcellona. La presentazione metterà in evidenza i dati aggiornati sull'efficacia e la sicurezza del trial di Fase 1 in corso, sottolineando il potenziale di questa terapia combinata nel trattamento dei pazienti con sarcomi refrattari, inclusi l'angiosarcoma viscerale e il leiomiosarcoma.
Botensilimab, un nuovo inibitore CTLA-4 potenziato da Fc, e balstilimab, un anticorpo anti-PD-1, hanno mostrato risposte cliniche promettenti in diversi tipi di tumore, inclusi i tumori 'freddi', tipicamente non responsivi alle terapie standard. La presentazione, intitolata 'Efficacia e sicurezza aggiornate di botensilimab più balstilimab in pazienti con sarcoma metastatico refrattario da uno studio di fase 1 ampliato,' sarà effettuata dalla Dr.ssa Breelyn A. Wilky il 13 settembre 2024.
Agenus Inc. (Nasdaq: AGEN) anunció que se presentarán datos actualizados del ensayo clínico de botensilimab y balstilimab en sarcomas refractarios en el Congreso ESMO 2024 en Barcelona. La presentación mostrará datos actualizados de eficacia y seguridad del ensayo de Fase 1 en curso, destacando el potencial de esta terapia combinada en el tratamiento de pacientes con sarcomas refractarios, incluidos el angiosarcoma visceral y el leiomiosarcoma.
Botensilimab, un nuevo inhibidor de CTLA-4 mejorado por Fc, y balstilimab, un anticuerpo anti-PD-1, han demostrado respuestas clínicas prometedoras en múltiples tipos de tumores, incluidos los tumores 'fríos', que normalmente son no responsivos a terapias estándar. La presentación, titulada 'Eficacia y seguridad actualizadas de botensilimab más balstilimab en pacientes con sarcoma metastásico refractario de un estudio ampliado de fase 1,' será realizada por la Dra. Breelyn A. Wilky el 13 de septiembre de 2024.
Agenus Inc. (Nasdaq: AGEN)가 바르셀로나에서 열리는 ESMO Congress 2024에서 botensilimab 및 balstilimab의 재발성 육종에 대한 임상 시험의 업데이트된 데이터를 발표할 것이라고 발표했습니다. 발표에서는 진행 중인 1상 시험의 업데이트된 효능 및 안전성 데이터를 선보이며, 이 조합 요법이 내성 육종 환자를 치료하는 데 있어 갖는 잠재력을 강조합니다. 내장형 혈관육종 및 평활근육종을 포함한 것입니다.
Botensilimab은 Fc가 강화된 새로운 CTLA-4 억제제이며, balstilimab은 PD-1 항체로서, 일반적으로 표준 치료에 반응하지 않는 '차가운' 종양을 포함한 여러 종양 유형에서 유망한 임상 반응을 보여주었습니다. 발표 제목은 '확장된 1상 연구에서 재발성 전이성 육종 환자에서의 botensilimab과 balstilimab의 업데이트된 효능 및 안전성'이며, 발표자는 2024년 9월 13일 Dr. Breelyn A. Wilky입니다.
Agenus Inc. (Nasdaq: AGEN) a annoncé que des données mises à jour de l'essai clinique de botensilimab et balstilimab dans les sarcomes réfractaires seront présentées lors du Congrès ESMO 2024 à Barcelone. La présentation mettra en avant les données mises à jour sur l'efficacité et la sécurité de l'essai de Phase 1 en cours, soulignant le potentiel de cette thérapie combinée dans le traitement des patients atteints de sarcomes réfractaires, y compris l'angiosarcome viscéral et le léiomyosarcome.
Botensilimab, un nouvel inhibiteur CTLA-4 amélioré par Fc, et balstilimab, un anticorps anti-PD-1, ont montré des réponses cliniques prometteuses dans plusieurs types de tumeurs, y compris les tumeurs 'froides' qui sont généralement non réceptives aux thérapies standard. La présentation, intitulée 'Efficacité et sécurité mises à jour de botensilimab plus balstilimab chez des patients atteints de sarcome métastatique réfractaire d'une étude de phase 1 élargie,' sera effectuée par Dr. Breelyn A. Wilky le 13 septembre 2024.
Agenus Inc. (Nasdaq: AGEN) gab bekannt, dass auf dem ESMO Kongress 2024 in Barcelona aktualisierte Daten aus der klinischen Studie zu botensilimab und balstilimab bei refraktären Sarkomen präsentiert werden. Die Präsentation wird aktualisierte Wirksamkeits- und Sicherheitsdaten aus der laufenden Phase-1-Studie hervorheben und das Potenzial dieser Kombinationstherapie zur Behandlung von Patienten mit refraktären Sarkomen, einschließlich viszeralem Angiosarkom und Leiomyosarkom, unterstreichen.
Botensilimab, ein neuartiger Fc-verbesserter CTLA-4-Inhibitor, und balstilimab, ein PD-1-Antikörper, haben vielversprechende klinische Reaktionen bei mehreren Tumorarten gezeigt, einschließlich 'kalter' Tumoren, die normalerweise auf Standardtherapien nicht ansprechen. Die Präsentation mit dem Titel 'Aktualisierte Wirksamkeit und Sicherheit von botensilimab plus balstilimab bei Patienten mit refraktärem metastatischem Sarkom aus einer erweiterten Phase-1-Studie' wird von Dr. Breelyn A. Wilky am 13. September 2024 gehalten.
- Presentation of updated efficacy and safety data from the Phase 1 trial at ESMO Congress 2024
- Potential therapeutic option for refractory sarcomas, including visceral angiosarcoma and leiomyosarcoma
- Promising clinical responses observed in multiple tumor types, including 'cold' tumors
- None.
The presentation will feature updated efficacy and safety data from the large, ongoing Phase 1 trial, highlighting the potential of this combination therapy in treating patients with refractory sarcomas, including visceral angiosarcoma and leiomyosarcoma, populations with limited therapeutic options. Botensilimab, a novel investigational Fc-enhanced CTLA-4 inhibitor, and balstilimab, an investigational PD-1 antibody, have shown promising clinical responses in multiple tumor types, including "cold" tumors that are typically unresponsive to standard therapies.
Presentation Details:
Abstract Title: Updated efficacy and safety of botensilimab plus balstilimab in patients with refractory metastatic sarcoma from an expanded phase 1 study
Abstract Number: 1726MO
Presenting Author: Breelyn A. Wilky, MD, University of Colorado Cancer Center
Session: Mini Oral Session, Sarcoma
Session Date and Time: Friday, September 13th, 2024, at 4:00 p.m. – 5:30 p.m. CEST (10:00 a.m. – 11:30 a.m. ET)
Complete abstracts are available through the ESMO Congress program. The presentation will also be available in the publications section of the Agenus website following the ESMO Congress on Friday, September 13th.
About Botensilimab
Botensilimab is an investigational human Fc enhanced CTLA-4 blocking antibody designed to boost both innate and adaptive anti-tumor immune responses. Its novel design leverages mechanisms of action to extend immunotherapy benefits to “cold” tumors which generally respond poorly to standard of care or are refractory to conventional PD-1/CTLA-4 therapies and investigational therapies. Botensilimab augments immune responses across a wide range of tumor types by priming and activating T cells, downregulating intratumoral regulatory T cells, activating myeloid cells and inducing long-term memory responses.
Approximately 1,100 patients have been treated with botensilimab in phase 1 and phase 2 clinical trials. Botensilimab alone, or in combination with Agenus’ investigational PD-1 antibody, balstilimab, has shown clinical responses across nine metastatic, late-line cancers. For more information about botensilimab trials, visit www.clinicaltrials.gov with the identifiers NCT03860272, NCT05608044, NCT05630183, and NCT05529316.
About Agenus
Agenus is a leading immuno-oncology company targeting cancer with a comprehensive pipeline of immunological agents. The company was founded in 1994 with a mission is to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants (through SaponiQx). Agenus has robust end-to-end development capabilities, across commercial and clinical cGMP manufacturing facilities, research and discovery, and a global clinical operations footprint. Agenus is headquartered in
Forward-Looking Statements
This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding its botensilimab and balstilimab programs, expected regulatory timelines and filings, and any other statements containing the words "may," "believes," "expects," "anticipates," "hopes," "intends," "plans," "forecasts," "estimates," "will," “establish,” “potential,” “superiority,” “best in class,” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of our most recent Annual Report on Form 10-K for 2023, and subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission. Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and Agenus undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240909215041/en/
Investors
917-362-1370
investor@agenusbio.com
Media
612-839-6748
communications@agenusbio.com
Source: Agenus Inc.
FAQ
What is the significance of Agenus' botensilimab and balstilimab presentation at ESMO 2024 for AGEN stock?
When and where will Agenus (AGEN) present the botensilimab and balstilimab data at ESMO 2024?
What types of cancers are being targeted by Agenus' (AGEN) botensilimab and balstilimab combination?
How can investors access Agenus' (AGEN) ESMO 2024 presentation on botensilimab and balstilimab?
